Powder: -20°C for 3 years | In solvent: -80°C for 1 year
HMGB1-IN-1 (compound 6) exhibits potent inhibition of NO production in RAW264.7 cells, with an IC50 of 15.9 ± 0.6 μM, and effectively disrupts the HMGB1/NF-κB/NLRP3 signaling pathway. This compound demonstrates promising anti-inflammatory and anti-sepsis properties, particularly in the context of renal injury [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | HMGB1-IN-1 (compound 6) exhibits potent inhibition of NO production in RAW264.7 cells, with an IC50 of 15.9 ± 0.6 μM, and effectively disrupts the HMGB1/NF-κB/NLRP3 signaling pathway. This compound demonstrates promising anti-inflammatory and anti-sepsis properties, particularly in the context of renal injury [1]. |
In vitro | HMGB1-IN-1 (compound 6) (0-30 μM, 0-48 h) not only reduces the levels of IL-1β and TNF-α in RAW264.7 and HK-2 cells but also exhibits a dose-dependent downregulation of NLRP3, P-NF-κB p65, and HMGB1 in activated HK-2 cells [1]. |
In vivo | HMGB1-IN-1 (compound 6), when administered intraperitoneally at doses ranging from 15 to 30 mg/kg, demonstrates potent anti-inflammatory activity [1]. |
Molecular Weight | 1042.22 |
Formula | C57H75N3O15 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.